Filter By Category
Archives
Share on -
ACTOXUMAB
Generic Name: ACTOXUMAB
ABSTRACT -
Actoxumab is an investigational human monoclonal antibody targeting Clostridioides difficile (C. difficile) toxin A. It was developed to prevent recurrence of C. difficile infection (CDI) by neutralizing toxin A activity. Actoxumab has been studied in combination with bezlotoxumab (which targets toxin B) in clinical trials for CDI prevention.
DOSAGE -
Actoxumab was evaluated as a single intravenous infusion (10 mg/kg) in clinical trials, typically in combination with bezlotoxumab. No approved dosage for routine clinical use, as clinical development has been largely discontinued based on trial outcomes showing limited additional benefit over bezlotoxumab alone.
SIDE EFFECTS –
Reported or potential side effects may include:
- Nausea
- Fatigue
- Headache
- Pyrexia
- Diarrhea
- Infusion-related reactions
- Hypertension
ALLRGIC REACTIONS–
(These symptoms may indicate an allergic reaction to the drug.)
- Hypersensitivity reactions
- Infusion reactions
- Anaphylaxis (rare)
- Urticaria
- Angioedema
DRUG INTERACTIONS–
- Bezlotoxumab (used in combination)
- Other monoclonal antibodies
- Immunosuppressive agents
PREAUTIONS–
- Standard precautions for monoclonal antibody administration.
- Monitor for infusion-related reactions.
- Safety in pregnancy not established.
- Renal and hepatic function monitoring advised.
- Not a treatment for active CDI; used for prevention of recurrence.
WARNINGS –
- Clinical utility as standalone therapy has not been established.
- Development largely superseded by bezlotoxumab monotherapy.
- Not currently in active regulatory approval process.
- Keep out of reach of children.
- All infusion-related events should be reported promptly.
Share on -
. Developed by